News & Analysis as of

Controlled Substances Public Health

Foley & Lardner LLP

New Mexico Becomes Third State in the U.S. to Legalize Access to Psilocybin

Foley & Lardner LLP on

On April 7, 2025, New Mexico Governor Michelle Lujan Grisham signed into law SB-219, the Medical Psilocybin Act (the Act), making New Mexico the third state in the country to create a legal pathway for patients to access...more

Nelson Mullins Riley & Scarborough LLP

Gold Dome Report - Legislative Day 32 - March 2025

While we spend much of our time watching bills and budgets under the Gold Dome, lawmakers and elected officials spend much of their time honoring constituents and other notable figures....more

Nelson Mullins Riley & Scarborough LLP

Gold Dome Report - Legislative Day 26 - March 2025

March came in like a lion on Monday as the Georgia General Assembly began its blitz toward Crossover Day on Thursday. With over 80 measures slated for hearing in House and Senate committees, state senators began their...more

Holland & Knight LLP

Holland & Knight Health Dose: February 19, 2025

Holland & Knight LLP on

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector....more

Foley & Lardner LLP

DEA Tightens Buprenorphine Telemedicine Prescribing Rules

Foley & Lardner LLP on

The Drug Enforcement Administration (DEA) and the U.S. Department of Health & Human Services (HHS) just finalized their March 2023 proposed rule regarding telemedicine prescribing of buprenorphine. The final rule, effective...more

Bennett Jones LLP

Supreme Court of Canada Endorses Comity in Class Proceedings in Response to the Opioid Epidemic

Bennett Jones LLP on

A national class action on behalf of multiple Canadian governments to recover opioid epidemic healthcare costs simplifies the aggregation, prosecution, and determination of claims that span geographic boundaries. That is what...more

Bradley Arant Boult Cummings LLP

MDMA DOA at FDA Advisory Committee

Avid readers know we have speculated that the legalization of psychedelics as a prescription medicine was “closer than ever.” Unfortunately, for proponents of the legalization of psychedelics like MDMA, progress is rarely a...more

Troutman Pepper Locke

Reassessing Oregon’s Drug Policy: A Shift Toward Recriminalization

Troutman Pepper Locke on

In the grand experiment of American democracy, it is often said that states serve as laboratories, testing policies that challenge the status quo without risking the stability of the whole. Oregon, known in recent years for...more

Console and Associates, P.C.

Parents Bring Kratom Lawsuits Following Overdose Deaths and Other Serious Injuries

Kratom, a natural substance derived from the leaves of the Mitragyna speciosa tree, has recently gained notoriety for its potential dangers. While proponents cite its therapeutic benefits, concerns have surged about its...more

Quarles & Brady LLP

It's (Apparently) Never Too Late Part II: DEA & Morris & Dickson Settle

Quarles & Brady LLP on

This week, DEA announced it has entered into a settlement agreement with Morris & Dickson Co., LLC (“Morris & Dickson”), resolving the protracted dispute born out of a May 2, 2018 Order to Show Cause (“OTSC”) and Immediate...more

Troutman Pepper Locke

Cannabis Plain Packaging Rules: Examples and Opportunities

Troutman Pepper Locke on

Much attention has recently been placed on hemp-derived products marketed in packaging that mimics popular snack foods. Originally published in Law360 - August 15, 2023....more

Womble Bond Dickinson

Chew on this...Xylazine Legislation Is Here

Womble Bond Dickinson on

Xylazine is a non-scheduled, non-opioid sedative/analgesic medication that is widely used in veterinary medicine. Xylazine was first produced by Bayer Pharmaceuticals in 1962, but investigations for use in humans were not...more

Cozen O'Connor

Congressional Efforts to Combat New Street Drug Threat Earn Bipartisan AG Support

Cozen O'Connor on

A bipartisan coalition of 39 AGs sent a letter to Congressional leaders urging the swift passage of the Combatting Illicit Xylazine Act, which would provide resources to fight the recent uptick in overdoses and deaths caused...more

Schwabe, Williamson & Wyatt PC

Washington Psilocybin Law Faces Delay

People hoping Washington would closely follow Oregon into the regulated use of psilocybin overseen by licensed practitioners faced a delay when a committee of the Washington legislature converted Senate Bill 5263 from...more

The Rodman Law Group, LLC

Colorado Voters Eye Decriminalization of Psilocybin

This November, Colorado could see some big changes in the area of psychedelics as activists believe they have enough signatures to place a measure on the state’s ballot that would legalize possession of psilocybin and create...more

Patrick Malone & Associates P.C. | DC Injury...

U.S. ends confusion and expands prescribing of opioid-fighting medication

Health workers with legal prescribing privileges have gotten newly revised federal guidelines — once again — making it easier for them to help those addicted to powerful opioid painkillers by prescribing buprenorphine,...more

Patrick Malone & Associates P.C. | DC Injury...

Consultant to pay $573.9 million as consequence of its sketchy opioid advice

The opioid abuse and drug overdose crisis has tarred yet another of the nation’s business titans: McKinsey, a globally renowned consulting firm, has discovered that providing corporate clients sketchy advice about addictive,...more

The Rodman Law Group, LLC

Oregon Takes the Lead on Drug Policy Reform

In the 2020 election, Oregon voters demonstrated an overwhelming appetite for drug policy reform. Election results show landslide victories for two groundbreaking measures – one decriminalizing all drugs, and one legalizing...more

Oberheiden P.C.

DEA Compliance for 2021 - How the DEA’s 2021 Proposed Aggregate Production Quotas Affect Pharmaceutical Companies and Society

Oberheiden P.C. on

The DEA struggles to balance the pressing need to provide pain relief for those suffering from the novel coronavirus with the ongoing effort to reduce the opioid epidemic in the United States. I. Overview on the DEA and the...more

Dorsey & Whitney LLP

Controlled Substance Prescribing Exceptions During Public Health Emergencies

Dorsey & Whitney LLP on

In light of the novel coronavirus pandemic, health care practitioners should be aware of relaxed guidelines for prescribing controlled substance. This blog post describes when practitioners can prescribe controlled substances...more

Polsinelli

Changes Coming For Prescribers To The Texas Prescription Drug Monitoring Program

Polsinelli on

In response to the opioid epidemic, many states, including Texas, created prescription drug monitoring programs to monitor high-risk patients and provider behaviors. The Texas Prescription Drug Monitoring Program (“PMP”) is...more

Troutman Pepper Locke

Protecting Your Company From Increased Scrutiny After Release of ARCOS Opioid Data

Troutman Pepper Locke on

In July, The Washington Post published data showing approximately 76 billion oxycodone and hydrocodone pills were purchased and sold in the Unites States from 2006 to 2012. The data came from the Automation of Reports and...more

Patrick Malone & Associates P.C. | DC Injury...

Another front in war on opioids: Criminal charges for Big Pharma execs, MDs

An estimated 400,000 Americans have died due to opioid drug overdoses between 1999 and 2017 — and the fatalities only are increasing. By 2025, according to expert forecasts, there will be 700,000 more opioid deaths....more

Bass, Berry & Sims PLC

Congress Takes Action to Curb the Opioid Crisis

Bass, Berry & Sims PLC on

In a bipartisan effort to combat the opioid crisis, H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (the Act), was enacted on October 24,...more

Morris James LLP

Prescription Monitoring Programs, Patient Privacy & SCOTUS

Morris James LLP on

In a previous post, we discussed how the opiate crisis has been blurring the lines in historic health policy, most recently as it comes to the tenability of taxes and fees on medications. Let’s now put on another pair of...more

28 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide